In 12 people with untreated social anxiety disorder, 600 mg of CBD taken 90 minutes before a simulated public speaking test reduced anxiety, cognitive impairment, and negative self-evaluation to levels statistically indistinguishable from healthy controls.
Read this if you have social anxiety and are considering CBD, or if you want to understand the strongest clinical evidence behind CBD for anxiety.
CBD brought anxious patients' scores to healthy control levels — anxiety, cognition, and self-evaluation all normalized
The Backstory
Imagine standing in front of a camera, knowing you're about to give a speech on public transportation to an audience of strangers — and knowing you have social anxiety disorder. Your hands sweat. Your mind floods with self-criticism. Your throat tightens.
Now imagine that ninety minutes earlier, you swallowed a capsule containing 600 milligrams of cannabidiol. And when the moment comes, you're... fine. Not drugged. Not sedated. Just not anxious. Your performance is indistinguishable from someone who's never had an anxiety disorder at all.
That's what happened in Mateus Bergamaschi's 2011 study — a small, elegant experiment that became one of the most cited pieces of evidence in the entire CBD anxiety literature.
The Experiment
The design was meticulous. Bergamaschi's team, working with senior researchers José Crippa and Antonio Zuardi at the University of São Paulo's Ribeirão Preto medical school — a group that has been studying cannabidiol since the early 1980s — screened 2,319 university undergraduates to find 24 people with diagnosed social anxiety disorder who had never been treated with any medication or psychotherapy.
This was deliberate. Treatment-naive patients provide the cleanest signal — no prior drug effects, no expectations based on past therapy, no confounding from medication washout periods. Finding them meant sifting through thousands of students with the MINI-SPIN screening tool, then confirming diagnoses with the gold-standard Structured Clinical Interview for DSM-IV.
The 24 patients were randomized double-blind: 12 received 600 mg of near-pharmaceutical-grade CBD (99.9% pure) in gelatin capsules, 12 received identical placebo capsules with corn oil. A third group of 12 healthy controls performed the same test with no medication at all.
Ninety minutes after swallowing their capsules, each participant faced the Simulated Public Speaking Test — a validated anxiety provocation paradigm. The instructions: prepare a four-minute speech on "the public transportation system of your city." You'll be videotaped. You'll watch yourself on a monitor while speaking. Researchers measured anxiety, cognitive impairment, discomfort, and alertness at six time points, along with physiological markers.
What Happened
CBD vs Placebo vs Healthy Controls
How 600mg CBD Affected Anxious Speakers
Normalized
Anxiety during speech
CBD group anxiety significantly lower than placebo (p=0.012)
Normalized
Cognitive impairment
CBD group significantly less impaired than placebo (p=0.009)
Normalized
Negative self-statements
Placebo increase 'almost abolished' by CBD
No difference
CBD vs healthy controls
On most measures, CBD group was indistinguishable from people without anxiety
Bergamaschi et al. (2011), Neuropsychopharmacology 36(6):1219-26
The results were striking in their clarity. Across nearly every psychological measure, the pattern was the same: the placebo group showed the expected spike in anxiety, cognitive impairment, and self-critical thinking during the speech — exactly what social anxiety disorder does. The CBD group showed virtually none of it. Their scores were statistically indistinguishable from the healthy controls who didn't have an anxiety disorder at all.
The Negative Self-Statement Scale captured this most vividly. Social anxiety disorder is fundamentally a disease of self-evaluation — the conviction that you're being judged and found wanting. The placebo group's negative self-statements spiked dramatically during the speech. The CBD group's barely moved. The researchers' precise language: the increase was "almost abolished."
Critically, CBD didn't achieve this by sedating participants. The sedation subscale showed that the placebo group was actually more alert (in the anxious, hypervigilant sense) during the anticipatory period before the speech. CBD reduced this hypervigilance without producing drowsiness — a differentiation that matters enormously for a potential anxiety medication.
How CBD Changes the Anxious Brain
A companion neuroimaging study by Crippa, published in the same year, provided the mechanism. Using SPECT brain imaging in 10 patients with social anxiety disorder who received 400 mg CBD or placebo, Crippa found that CBD decreased blood flow to the parahippocampal gyrus, hippocampus, and inferior temporal gyrus — limbic and paralimbic regions that drive the anxiety response — while increasing activity in the posterior cingulate gyrus.
Biological Mechanism
How CBD Reduces Social Anxiety
CBD enters the brain
After oral administration, CBD crosses the blood-brain barrier. Peak plasma levels occur 1-2 hours post-dose.
Limbic activity decreases
CBD reduces blood flow to the parahippocampal gyrus and hippocampus — key regions in threat processing and anxious memory retrieval.
Amygdala response dampened
The amygdala, the brain's alarm system, receives less excitatory input from connected limbic structures.
Self-referential processing normalizes
Reduced limbic drive means less catastrophic self-evaluation — the negative self-talk that defines social anxiety.
Subjective experience: calm without sedation
Unlike benzodiazepines, CBD doesn't impair cognition or produce drowsiness. The anxious brain quiets; the thinking brain keeps working.
Crippa et al. (2011), J Psychopharmacol; Bergamaschi et al. (2011)
This mechanism — limbic quieting without cortical suppression — explains why CBD doesn't feel like a traditional anxiolytic to users. Benzodiazepines work by broadly enhancing GABA inhibition across the brain, which reduces anxiety but also impairs memory, coordination, and alertness. CBD appears to target the anxiety circuit more selectively, reducing the emotional overreaction without compromising the cognitive machinery.
The Dose Question
The 600 mg dose used in this study is far higher than what most people take. A typical CBD gummy contains 25 mg. Even "high-dose" commercial products rarely exceed 50 mg per serving. At 600 mg of pharmaceutical-grade CBD, Bergamaschi's participants were taking 12 to 24 times the standard consumer dose — and it would cost $30-60 per dose at retail CBD prices.
Subsequent work from the same research group has complicated the dose picture:
Dosing
CBD and Anxiety: The Inverted U
300 mg
In a 2017 follow-up by Zuardi and Crippa, 300 mg CBD was anxiolytic in healthy volunteers during public speaking — equivalent to this study's 600 mg in some measures.
600 mg
The dose used in this study. Clearly effective for social anxiety disorder.
150 mg
Less effective than 300 mg in the follow-up study — possibly below the therapeutic threshold for acute anxiety.
900 mg
Not tested in this paradigm, but other research suggests very high CBD doses may be less effective — the inverted U dose-response pattern seen with many anxiolytics.
Consumer doses (10-50 mg)
Not tested in any rigorous clinical trial for anxiety. Whether typical retail CBD doses produce meaningful anxiolytic effects is genuinely unknown.
Zuardi et al. (2017), Front Pharmacol; Bergamaschi et al. (2011)
This is the elephant in the room for the entire CBD anxiety market. The dose that works in clinical trials is 6 to 60 times higher than what people typically buy. Whether the low doses in commercial products do anything meaningful for anxiety has never been rigorously tested — and the inverted U curve suggests the relationship between dose and effect isn't linear. More isn't necessarily better, but less may not be enough.
Where This Study Sits
Research Timeline
Historical research record
This study didn't emerge from nowhere. It came from a Brazilian research group — Crippa, Zuardi, Hallak, and collaborators at the University of São Paulo — that has been studying cannabidiol continuously since the early 1980s. Their work represents one of the longest-running CBD research programs in the world, spanning animal studies, healthy volunteer trials, neuroimaging, and now clinical populations. Bergamaschi's 2011 study was the culmination of nearly three decades of groundwork.
The Credibility Assessment
Supporting arguments
- Published in Neuropsychopharmacology (impact factor ~7) — a top-tier psychiatric neuroscience journal
- Double-blind, randomized, placebo-controlled with healthy control comparison — rigorous for a preliminary study
- Treatment-naive patients eliminate medication confounds entirely
- Ecological validity: the SPST is a validated, clinically meaningful anxiety provocation
- Statistical power was excellent (0.996 for anxiety measure) despite small sample
- Builds on 30 years of prior work from the same group — not an isolated finding
- Companion neuroimaging study provides a plausible biological mechanism
Limitations and counterarguments
- Only 12 patients per group — too small to detect moderate effects or adverse events
- Single-dose study — no information about repeated dosing, tolerance, or long-term effects
- 600 mg dose is impractical and unaffordable for most real-world use
- Lab-based anxiety provocation doesn't capture the complexity of daily social anxiety
- Predominantly young, university-educated Brazilian sample — limited generalizability
- Treatment-naive patients may respond differently than the typical treatment-seeking patient with medication history
- No completed large-scale RCT has validated repeated CBD dosing for clinical anxiety disorders as of 2026
Bergamaschi et al. (2011)
The core finding is robust within its scope: a single high dose of pharmaceutical-grade CBD reduces acute social anxiety to near-normal levels under controlled conditions. That's real. What hasn't been established is whether this translates to meaningful, sustained anxiety relief in everyday life at doses people can actually afford and access. The gap between "600 mg of 99.9% pure CBD normalizes lab anxiety" and "a 25 mg CBD gummy from a gas station helps you at parties" is enormous — and largely unstudied.
The quality of the CBD product matters enormously. Research-grade CBD is a different substance from most consumer products, which vary wildly in actual CBD content, contain unknown contaminants, and may have different bioavailability profiles.
Why This Study Won't Go Away
Despite its small size and single-dose design, Bergamaschi 2011 has become a cornerstone citation for several reasons. First, the effect size was large and clean — not a marginal, statistically-massaged finding, but a dramatic normalization of anxiety. Second, the mechanism was simultaneously established via neuroimaging. Third, no serious adverse effects were observed. And fourth, it addressed a condition — social anxiety disorder — that affects roughly 12% of people worldwide, is frequently undertreated, and for which existing medications (SSRIs, benzodiazepines) carry significant baggage.
For people weighing their options between an SSRI (which takes weeks to work, can cause sexual dysfunction and weight gain, and has withdrawal effects) and CBD (which works acutely, has minimal side effects, but has far less clinical evidence), this study is the single strongest data point in CBD's favor. It's not enough to base a clinical recommendation on — but it's enough to justify taking the question seriously.
Key Takeaways
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients
Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JEC, Zuardi AW, Crippa JAS (2011) · Neuropsychopharmacology
Does CBD help with social anxiety?
In this study, a single high dose (600 mg) of pharmaceutical-grade CBD significantly reduced anxiety during a controlled public speaking test. The effect was large and clean. But this doesn't mean CBD gummies from a dispensary will work for your social anxiety — the dose was 12-24 times higher than typical products, the CBD was near-pure pharmaceutical grade, and it was tested in a specific lab scenario, not daily life.
How much CBD do I need for anxiety?
The clinical evidence suggests 300-600 mg for acute anxiety effects, based on this study and follow-ups. Most consumer products contain 10-50 mg per serving. Whether low doses have meaningful effects hasn't been rigorously studied. The dose-response appears to be an inverted U — meaning more isn't necessarily better, but very little may not be enough.
Is CBD better than SSRIs for anxiety?
There isn't enough evidence to make that comparison. SSRIs have decades of large RCTs supporting their use. CBD has a handful of small trials. SSRIs take weeks to work but provide sustained relief. CBD may work acutely but its long-term efficacy for anxiety hasn't been established in clinical trials. They also work through entirely different mechanisms and have different side effect profiles.
Why haven't there been larger CBD anxiety trials?
Several factors: CBD isn't patentable in its natural form, reducing pharmaceutical industry incentive; regulatory barriers in many countries; the difficulty of blinding studies (CBD has a distinctive taste and mild physiological effects); and the challenge of standardizing dosing across the wide range of CBD products people actually use. Multiple trials are in progress as of 2026, but none have yet produced definitive large-scale results for anxiety disorders.
What the researchers found
Twenty-four treatment-naive SAD patients were randomized to CBD 600 mg (n=12) or placebo (n=12), with 12 healthy controls. CBD significantly reduced anxiety (p=0.012), cognitive impairment (p=0.009), and discomfort (p=0.029) during public speaking versus placebo. Negative self-statements were "almost abolished" by CBD. No significant differences between CBD and healthy controls on most measures (SSPS-N, cognitive impairment, discomfort, alertness subscales of VAMS). Statistical power: 0.996 for primary anxiety measure.
Why it matters
This study provided the clearest evidence to date that CBD could normalize clinical anxiety to healthy control levels without sedation or cognitive impairment — differentiating it from benzodiazepines. Combined with companion neuroimaging showing CBD reduces limbic brain activity, it established CBD as a serious anxiolytic candidate with a plausible mechanism. It became the foundational citation for the entire CBD anxiety research field and the CBD wellness market.
The numbers in context
24 SAD patients (12 CBD, 12 placebo) + 12 healthy controls. CBD dose: 600 mg, single dose. Significant reductions in anxiety, cognitive impairment, discomfort, and negative self-statements. CBD group scores were similar to healthy controls.
How the study worked
Double-blind, randomized, placebo-controlled study with healthy control group. 2,319 undergraduates screened with MINI-SPIN; 24 treatment-naive SAD patients confirmed by SCID-CV. CBD group received 600 mg (~99.9% pure) in gelatin capsules 90 min before Simulated Public Speaking Test (4-min speech, videotaped). Measured: Visual Analogue Mood Scale (VAMS — 4 factors), Negative Self-Statement Scale (SSPS-N), Bodily Symptoms Scale (BSS), heart rate, blood pressure, skin conductance at 6 time points. FAPESP-funded. Repeated-measures ANOVA with Bonferroni correction.
What this study cannot tell us
Only 12 patients per group. Single-dose study with no information on repeated dosing, tolerance, or durability. 600 mg dose is impractical and expensive for real-world use. Simulated public speaking does not capture daily social anxiety. Young Brazilian university student sample limits generalizability. Treatment-naive patients may respond differently than typical treatment-seeking patients. No adverse event power with 12 subjects.
How to read the evidence
Double-blind, randomized, placebo-controlled trial in a diagnosed clinical population with a healthy control comparison — strong design. But only 12 per group, single dose, and no large-scale replication for clinical anxiety.
When this study was published
Published in 2011. Remains the most cited CBD anxiety RCT. The research group has published dose-finding and neuroimaging follow-ups, but no large-scale clinical anxiety trial has been completed.
The bigger picture
Bergamaschi 2011 is the most cited single study supporting CBD for anxiety, but the field has been slow to advance beyond it. No completed large-scale RCT of repeated CBD dosing for clinical anxiety disorders exists as of 2026. The gap between this proof-of-concept (600 mg pharmaceutical-grade, single dose, lab setting) and real-world use (low-dose consumer products for daily anxiety) remains largely unstudied.
Questions still open
- Would lower doses (100-300 mg) work for clinical SAD? Does repeated CBD dosing maintain efficacy over weeks/months? How does CBD compare to SSRIs in a head-to-head trial? Does CBD work for generalized anxiety as well as situational/performance anxiety? Do consumer-grade CBD products at typical doses (10-50 mg) produce any meaningful anxiolytic effect?
Common questions
Does CBD work for social anxiety?
How much CBD do I need to reduce anxiety?
Is CBD sedating?
Read the original research
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 36(6), 1219-26
Citation
Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; de Oliveira, Danielle Chaves Gomes; De Martinis, Bruno Spinosa; Kapczinski, Flávio; Quevedo, João; Roesler, Rafael; Schröder, Nadja; Nardi, Antonio E; Martín-Santos, Rocio; Hallak, Jaime Eduardo Cecílio; Zuardi, Antonio Waldo; Crippa, José Alexandre S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 36(6), 1219-26. https://doi.org/10.1038/npp.2011.6
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- Why Does Weed Make You Paranoid? The Amygdala Connection
- Why Does Weed Make Me Anxious Now When It Didn't Before
- THC and Benzodiazepines: The Dangerous Overlap Nobody Discusses
- Cannabis and Socializing: Why Some People Only Use Around Others